Catch up on the top radiology content of the past week.
|Articles|August 19, 1998
FDA clears ELGEMS artifact correction
The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by
Advertisement
The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by ELGEMS, which are sold by Elscint as VariCam and by GE Medical Systems as Millennium VG. Elscint plans to begin shipments of VTransACT for VariCam in the first quarter of 1999, according to a spokesperson for the company. ELGEMS also received 510(k) clearance for a set of ultra-high-energy collimators, called VPC-94. The collimators are designed to be used on VariCam for FDG cardiac imaging.
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
4
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
5